Susan O’Brien MD
University of California Irvine Medical Center, USA
Susan O’Brien MDUniversity of California Irvine Medical Center, USA
Susan M. O’Brien, M.D., is a professor in the department of leukemia and clinical consultant and special assistant to the physician-in-chief at MD Anderson Cancer Center. Dr. O’Brien received her medical degree from the University of Medicine and Dentistry of New Jersey in Newark. She went on to complete a residency in internal medicine at the University of Medicine and Dentistry of New Jersey. She served there as an instructor in medicine before moving to California, where she served as an instructor in the San Fernando Valley Program in the University of California, Los Angeles School of Medicine and an internist in the University of Southern California Student Health Service. During her time at MD Anderson, Dr. O’Brien has been the principal investigator or a co-principal investigator for 5 funded research projects and the primary investigator for more than 20 funded protocols. In addition, she has served on the Translational Research Study Section for the Leukemia and Lymphoma Society since 2001.
Next Questions in CLL
Anna Schuh MD
University of Oxford, UK
Anna Schuh MDUniversity of Oxford, UK
Professor Anna Schuh is the Director of Molecular Diagnostics at the University of Oxford and an Honorary Consultant Haematologist. She is the clinical lead for chronic lymphocytic leukaemia (CLL) and other lymphoproliferative disorders for the NHS Thames Valley Cancer Network.
Over the past ten years she has led over 30 early and late phase clinical trials in CLL as a principle or national chief investigator. A number of these led to NICE approvals and have changed clinical practice for patients with CLL in the UK and worldwide. She chaired the UK CLL Forum from 2016 to 2019 that aims to promote research and education in CLL nationally and she led the treatment guidelines writing group for CLL on behalf of the British Society of Haematology. In August 2018, she was appointed as the chair for the National Cancer Research Institute CLL working group.
NGS in CLL, what does it add